Back to search

Peptide record

TPDB10038

Moronecidin Piscidin 1 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10038
Moronecidin Piscidin 1
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb dbAMP 3.0 AI4AVP DRAVP 2.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 22-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FFHHIFRGIVHVGKTIHRLVTG
Physicochemical Analysis
C122H187N37O25
ANDCEQMPSWY
H
2572.06
12.41
7
0
10
+3
2.09
0.455
110.45
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
0
Q
3
G
4
H
3
I
1
L
1
K
0
M
3
F
0
P
0
S
2
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 4 I: 3 L: 1 K: 1 M: 0 F: 3 P: 0 S: 0 T: 2 W: 0 Y: 0 V: 3
Chemical Descriptors
22
C122H187N37O25
2572.06
12.41
+3
2.09
0.455
Free
L
Not Available Linear
Free
Antibacterial Anticancer
Hybrid striped bass (Morone saxatilis x M. chrysops) Morone saxatilis
Evidence Records 40 records
Evidence 1 Activity

Activity

MIC
Antibacterial
12.5 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA3
Evidence 2 Activity

Activity

MIC
Antibacterial
50 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP

Other

Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( K
Evidence 3 Activity

Activity

MIC
Antibacterial
12.5 µM

Target

B. subtilis

Source & Reference

dbAMP DRAMP

Other

Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( Kim JP et al 2010 ) ( Menousek J et al 2012
Evidence 4 Activity

Activity

MIC
Antibacterial
1-4 µM

Target

Staphylococcus aureus USA300 or MRSA

Source & Reference

dbAMP DRAMP

Other

(MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( Kim JP et al 2010 ) ( Menousek J et al 2012 ). fungi: C.albicans (MIC > 125 ug/ml). Vir
Evidence 5 Activity

Activity

Not Available
Anticancer

Target

Breast Cancer
Not Available
Not Available

Assay & Model

Not Available
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2001

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 6 Activity

Activity

IC50
IC50 = 5.58 µM
Anticancer
5.58 µM

Target

Fibrosarcoma
HT-1080
Not Available

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2021
Evidence 7 Activity

Activity

IC50
IC50 = 5.83 µM
Anticancer
5.83 µM

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2021
Evidence 8 Activity

Activity

IC50
IC50 = 4.2 µM
Anticancer
4.2 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2021
Evidence 9 Activity

Activity

IC50
IC50 = 2.22 µM
Anticancer
2.22 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2021
Evidence 10 Activity

Activity

MIC
Antifungal
12.5 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA3
Evidence 11 Activity

Activity

MIC
Antifungal
50 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( K
Evidence 12 Activity

Activity

MIC
Antifungal
12.5 µM

Target

B. subtilis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( Kim JP et al 2010 ) ( Menousek J et al 2012
Evidence 13 Activity

Activity

MIC
Antifungal
1-4 µM

Target

Staphylococcus aureus USA300 or MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

(MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( Kim JP et al 2010 ) ( Menousek J et al 2012 ). fungi: C.albicans (MIC > 125 ug/ml). Vir
Evidence 14 Activity

Activity

MIC
Antiparasitic
12.5 µM

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA3
Evidence 15 Activity

Activity

MIC
Antiparasitic
50 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( K
Evidence 16 Activity

Activity

MIC
Antiparasitic
12.5 µM

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( Kim JP et al 2010 ) ( Menousek J et al 2012
Evidence 17 Activity

Activity

MIC
Antiparasitic
1-4 µM

Target

Staphylococcus aureus USA300 or MRSA

Source & Reference

dbAMP 3.0 DRAMP

Other

(MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( Kim JP et al 2010 ) ( Menousek J et al 2012 ). fungi: C.albicans (MIC > 125 ug/ml). Vir
Evidence 18 Activity

Activity

MIC
Antiviral
12.5 µM

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA3
Evidence 19 Activity

Activity

MIC
Antiviral
50 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( K
Evidence 20 Activity

Activity

MIC
Antiviral
12.5 µM

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli (MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( Kim JP et al 2010 ) ( Menousek J et al 2012
Evidence 21 Activity

Activity

MIC
Antiviral
1-4 µM

Target

Staphylococcus aureus USA300 or MRSA

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

(MIC 12.5 uM), P. aeruginosa (MIC 50 uM), S. typhimurium, B. subtilis (MIC 12.5 uM), and S. aureus USA300 or MRSA (MIC 1-4 uM) ( Kim JP et al 2010 ) ( Menousek J et al 2012 ). fungi: C.albicans (MIC > 125 ug/ml). Vir
Evidence 22 Activity

Activity

% Hemolysis
Hemolysis
10 60 100 %
[Ref.11713517]10% hemolytic activity at 5 µg/mL, 60% hemolytic activity at 10 µg/mL, 100% hemolytic activity at 50 µg/mL against human erythrocytes

Target

human erythrocytes

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Nature. 2001 Nov 15 414(6861):268-269.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 23 Activity

Activity

0% Hemolysis
Toxicity
0.78 µM
Hemolytic Cytotoxic
0% Hemolysis | 0.78 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Fungicidal effect of piscidin on Candida albicans: pore formation in lipid vesicles and activity in fungal membranes. | Biol Pharm Bull | 2008
Evidence 24 Activity

Activity

9% Hemolysis
Toxicity
1.56 µM
Hemolytic Cytotoxic
9% Hemolysis | 1.56 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Fungicidal effect of piscidin on Candida albicans: pore formation in lipid vesicles and activity in fungal membranes. | Biol Pharm Bull | 2008
Evidence 25 Activity

Activity

45% Hemolysis
Toxicity
3.125 µM
Hemolytic Cytotoxic
45% Hemolysis | 3.125 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Fungicidal effect of piscidin on Candida albicans: pore formation in lipid vesicles and activity in fungal membranes. | Biol Pharm Bull | 2008
Evidence 26 Activity

Activity

92% Hemolysis
Toxicity
6.25 µM
Hemolytic Cytotoxic
92% Hemolysis | 6.25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Fungicidal effect of piscidin on Candida albicans: pore formation in lipid vesicles and activity in fungal membranes. | Biol Pharm Bull | 2008
Evidence 27 Activity

Activity

96% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
96% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Fungicidal effect of piscidin on Candida albicans: pore formation in lipid vesicles and activity in fungal membranes. | Biol Pharm Bull | 2008
Evidence 28 Activity

Activity

100% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
100% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Fungicidal effect of piscidin on Candida albicans: pore formation in lipid vesicles and activity in fungal membranes. | Biol Pharm Bull | 2008
Evidence 29 Activity

Activity

50% Hemolysis
Toxicity
15 µM
Hemolytic Cytotoxic
50% Hemolysis | 15 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Single amino acid substitutions at specific positions of the heptad repeat sequence of piscidin-1 yielded novel analogs that show low cytotoxicity as well as in vitro and in vivo anti-endotoxin activity. | Antimicrob Agents Chemother | 2016
Evidence 30 Activity

Activity

100% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
100% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Piscidin-1-analogs with double L- and D-lysine residues exhibited different conformations in lipopolysaccharide but comparable anti-endotoxin activities. | Sci Rep | 2017
Evidence 31 Activity

Activity

50% Hemolysis
Toxicity
3.12 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 3.12 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Substitution of lysine for isoleucine at the center of the nonpolar face of the antimicrobial peptide, piscidin-1, leads to an increase in the rapidity of bactericidal activity and a reduction in toxicity. | Infect Drug Resist | 2019
Evidence 32 Activity

Activity

100% Hemolysis
Toxicity
25 µg/mL
Hemolytic Cytotoxic
100% Hemolysis | 25 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Substitution of lysine for isoleucine at the center of the nonpolar face of the antimicrobial peptide, piscidin-1, leads to an increase in the rapidity of bactericidal activity and a reduction in toxicity. | Infect Drug Resist | 2019
Evidence 33 Activity

Activity

LC90
Toxicity
50 µg/mL
Cytotoxic
LC90 | 50 | µg/mL | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Substitution of lysine for isoleucine at the center of the nonpolar face of the antimicrobial peptide, piscidin-1, leads to an increase in the rapidity of bactericidal activity and a reduction in toxicity. | Infect Drug Resist | 2019
Evidence 34 Activity

Activity

50% Cytotoxicity
Toxicity
65.2 µg/mL
Cytotoxic
50% Cytotoxicity | 65.2 | µg/mL | target cell: Pig kidney epithelial cells PK15

Target

Pig kidney epithelial cells PK15

Source & Reference

NA
DBAASP
Antiviral activity of Piscidin 1 against pseudorabies virus both in vitro and in vivo | Virol J | 2019
Evidence 35 Activity

Activity

50% Hemolysis
Toxicity
11 µM
Hemolytic Cytotoxic
50% Hemolysis | 11 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Solution structure and cell selectivity of piscidin 1 and its analogues. | Biochemistry | 2007
Evidence 36 Activity

Activity

50% Cell death
Toxicity
6.9 µM
Cytotoxic
50% Cell death | 6.9 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. | Antimicrob Agents Chemother | 2010
Evidence 37 Activity

Activity

50% Hemolysis
Toxicity
20 µM
Hemolytic Cytotoxic
50% Hemolysis | 20 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300. | Int J Antimicrob Agents | 2012
Evidence 38 Activity

Activity

10% Cytotoxicity
Toxicity
100 µg/mL
Cytotoxic
10% Cytotoxicity | 100 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Fish-derived cationic antimicrobial peptide piscidin 1 exerts broad-spectrum bactericidal activities against multidrug-resistant Gram-negative pathogens | LWT | 2025
Evidence 39 Activity

Activity

Toxicity
Hemolytic
Hemolytic_activity: [Ref.11713517]10% hemolytic activity at 5 µg/mL, 60% hemolytic activity at 10 µg/mL, 100% hemolytic activity at 50 µg/mL against human erythrocytes

Target

erythrocytes

Source & Reference

NA
DRAMP
Nature. 2001 Nov 15 414(6861):268-269.
Evidence 40 Hemolysis

Activity

10 60 100 %
% Hemolysis
[Ref.11713517]10% hemolytic activity at 5 µg/mL, 60% hemolytic activity at 10 µg/mL, 100% hemolytic activity at 50 µg/mL against human erythrocytes
Hemolysis

Target

human erythrocytes

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
Nature. 2001 Nov 15 414(6861):268-269.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.